Purdue Pharma announced the discontinuance of Dilaudid-HP (hydromorphone HCl) Injection 50mL single dose vials and Dilaudid-HP Injection Sterile Lyophilized Powder 250mg vials as of July 27, 2015. The Company stated that no new orders were being shipped because there is no more inventory of these products.

RELATED: U.S. Medical Groups Fighting Prescription Opioid Abuse

Both Dilaudid-HP products are opioid narcotics indicated for the management of moderate-to-severe pain in opioid-tolerant patients who require higher doses of opioids. Hydromorphone HCl is a mu-opioid receptor agonist whose principal therapeutic action is analgesia. The precise mode of analgesic action of opioid analgesics is unknown but specific CNS opiate receptors have been identified.

For more information call (800) 877-5666 or visit PurduePharma.com.